Skip to main content
Premium Trial:

Request an Annual Quote

IntegenX and NuGen Will Automate Sequencing Sample Prep Workflows


This story was originally published on April 7.

IntegenX and NuGen Technologies will collaborate to automate NuGen's next-gen sequencing sample prep workflows on IntegenX's Apollo series systems, the companies said today.

Under the terms of the agreement, NuGen's Ovation RNA-seq kit will be the first to be automated on the Apollo 324 system and will be available commercially this year. The financial terms were not disclosed.

The system will be able to process up to 32 samples, each with as little as 500 picograms of total RNA, and will be well-suited for clinical samples such as circulating tumor cells and fine needle aspirates, as well as biobanked tissue collections, according to the companies.

Automating NuGen's sample-prep workflows makes it "practical for researchers to include large-scale studies on preserved tissues and small cell populations in the process of solving biological problems," IntegenX's CEO Stevan Jovanovich said in a statement.

NuGen is also collaborating with Caliper to automate its RNA-seq sample-prep method and other sample-prep methods on Caliper's Sciclone NGS Workstation (IS 2/1/2011).

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.